WHY HIRE A CHIEF MEDICAL RESEARCH OFFICER
with experience in global drug approval processes? And then this stock goes up in price 10%, more or less and after an announcement of a CLR131 clinical data release is scheduled for 2-19-20?
Cellectar Appoints Dr. Igor Grachev as Chief Medical Officer
BY GlobeNewswire
— 8:00 AM ET 01/07/2020
FLORHAM PARK, N.J., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. ( CLRB
CLRB, “...a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced it has appointed Dr. Igor Grachev as Chief Medical Officer.
“I am excited to welcome Igor to our senior management team as Chief Medical Officer. Igor possesses outstanding academic training and a track record of professional success with highly relevant experiences including multiple global oncology drug approvals ,” said Jim Caruso, CEO of Cellectar. “We look forward to his leadership as we advance our pipeline of assets and work towards fully developing the potential of CLR 131.”
Igor Grachev, M.D., Ph.D., brings nearly 20 years of industry experience to Cellectar having led clinical development programs at both multinational pharmaceutical and biotech organizations. He served as Global Development Leader and Head of Innovative Clinical Trials Initiative, R&D for TEVA Branded Specialty Pharmaceuticals, where he was responsible for the development, execution and management of clinical programs worldwide across all phases of clinical research, achieving regulatory approvals in multiple countries. Dr. Grachev also had clinical development and medical affairs leadership roles at GE Healthcare, Novartis, GSK, Merck, Schering Plough, Sanofi-”
AND WHY GIVE HIM A 80,000 common shares stock option as shown in a subsequent SEC filing regarding a Power of Attorney filing for 4 people to make SEC Form 4 STOCK TRANSACTION notices for him?
SOMETHING IMPORTANT IS ABOUT TO HAPPEN, MAYBE NEXT SUNDAY?
